(2S,4S)-Methyl 1-Benzyl-4-Hydroxypyrrolidine-2-Carboxylate

Sustaining ≤10 ppm Residual Palladium After Hydrogenolytic Debenzylation of the Omapatrilat Intermediate

Meeting the 10 ppm palladium threshold stipulated in the EMA Guideline on the Specification Limits for Residues of Metal Catalysts (EMEA/CHMP/SWP/4446/2000) for the synthesis of the NEP/ACE dual inhibitor omapatrilat forces a narrow process window when hydrogenating the N‑benzyl group of this intermediate. The protected cis‑hydroxyproline scaffold is condensed with a triphenylmethyl‑protected thioacetate derivative at a molar input of 1.12 equivalents relative to the pyrrolidine ester in a dichloromethane/tetrahydrofuran mixture at −15 ± 2°C using diethyl azodicarboxylate (1.25 eq) and triphenylphosphine, a step that produces the key mercaptoazepinone precursor while locking the (2S,4S) configuration. Adiabatic reaction calorimetry (Mettler Toledo RC1e) on a 20‑L vessel revealed that the Mitsunobu‑type coupling exhibits an exotherm of −178 kJ/mol with a thermal accumulation peak if the DIAD addition rate exceeds 4.2 mL/min; the jacket temperature controller must maintain the mass temperature within a ±1.5°C deadband to prevent epimerisation at C‑4, detectable as the (2S,4R) diastereomer impurity (>0.15 area% by chiral SFC). Subsequent catalytic transfer hydrogenation with 5% Pd/C (50% wet paste) under 3.5 bar H₂ pressure at 25°C removes the benzyl protection, but the process is susceptible to over‑reduction and Pd leaching if the hydrogen uptake deviates from a consumption profile of 2.8–3.1 L/kg substrate; post‑reaction chelation with trimercaptotriazine‑functionalised silica before hot filtration ensures the Pd content drops below the 10 µg/g limit, verified by ICP‑MS according to USP <233>. The full manufacturing chain operates under ICH Q7-compliant GMP conditions, and the resulting thiol‑containing intermediate is telescoped directly into the final acylation to produce omapatrilat hemiketal, subsequently formulated as immediate‑release oral tablets containing 10 mg, 25 mg, or 50 mg of the vasopeptidase inhibitor.

In the synthesis of macrocyclic HCV NS3/4A protease inhibitors, the (2S,4S)‑methyl 1‑benzyl‑4‑hydroxypyrrolidine‑2‑carboxylate is deliberately selected as the starting chiral pool material because its cis geometry increases the steric compression around the pyrrolidine nitrogen, thereby retarding the competing intramolecular cyclisation to a bicyclic lactam during solid‑phase or solution‑phase peptide elongation. The downstream process converts the intermediate into a trans‑4‑aryloxy‑L‑proline fragment through a stereospecific Mitsunobu inversion with 4‑hydroxy‑7‑methoxy‑2‑phenylquinoline; a molar ratio of 1.8 equivalents of the phenol nucleophile to the hydroxyl‑bearing substrate is used, together with tri‑n‑butylphosphine (1.5 eq) and di‑tert‑butyl azodicarboxylate (1.5 eq). In a kilogram‑scale batch conducted in a 100‑L glass‑lined reactor under nitrogen inertisation, the addition sequence is reversed – the phosphine and azodicarboxylate are pre‑mixed at 0°C before the phenol is charged – to avoid formation of a hydrazodicarboxylate precipitate that fouls the heat‑transfer surfaces. USP <467> residual solvent analysis and ICH Q3C Class 2 limits are applied to the isolated aryl ether (acetonitrile ≤410 ppm, dichloromethane ≤600 ppm). The trans‑configured amino ester is then coupled into the P2 position of the linear peptidomimetic chain and cyclised to deliver the macrocyclic core of agents such as danoprevir or asunaprevir, which are finally formulated as hard gelatin capsules for antiviral therapy.

Asymmetric Michael Addition Catalysis with a 4‑Siloxy‑Substituted Pyrrolidine Derivative Under Non‑Cryogenic Temperatures

Derivatisation of the free hydroxyl group of the (2S,4S)‑1‑benzyl‑4‑hydroxypyrrolidine‑2‑carboxylate ester with tert‑butyldimethylsilyl chloride in the presence of imidazole generates a bulky organocatalyst that promotes the enantioselective conjugate addition of aldehydes to nitroalkenes at ambient temperatures, circumventing the need for energy‑intensive cryogenic cooling. The catalyst loading is typically 2.5 mol% relative to the aldehyde donor, with the reaction mass stirred in a simple batch vessel at 22 ± 3°C; propanal addition to β‑nitrostyrene proceeds to 93% conversion in 8 hours with an enantiomeric excess of 91% as determined by chiral GC‑FID on a CycloSil‑B column. Compliance with monograph requirements for the resultant γ‑nitroaldehyde – a penultimate intermediate for gabapentinoid preparation – requires that the residual organocatalyst be reduced below 0.10% (w/w), which is achieved by silica gel plug filtration followed by treatment with activated carbon (Norit SX Ultra) at 50°C for 3 hours, validated by HPLC‑CAD. The methyl ester moiety of the original scaffold is retained in the catalyst and permits recovery through aqueous acid extraction, though re‑use beyond the third cycle shows a 12% erosion in diastereomeric excess due to gradual degradation of the silyl ether under mildly acidic aqueous work‑up.

Direct integration of (2S,4S)-methyl 1‑benzyl‑4‑hydroxypyrrolidine‑2‑carboxylate as a comonomer into the amorphous segment of a biodegradable poly(ester amide) is practiced when a controlled introduction of stereocenters is required to reduce the crystallisation rate of the polymer for soft‑tissue engineering scaffolds. The monomer, after drying to a water content <0.03% (Karl Fischer), is charged at 18–22 mol% of the total diol pool alongside 1,6‑hexanediol and dimethyl succinate, and the prepolymer is synthesised through a two‑stage melt polycondensation at 160°C under 500 mbar for 3 hours followed by 210°C at 1 mbar for 6 hours in a 10‑L Büchi glass polycondensation rig, subsequently scaled to an intermeshing co‑rotating twin‑screw extruder (L/D 44) with a vacuum devolatilisation zone. The resulting copolyester amide must satisfy ISO 10993‑5 cytotoxicity testing (elution method, L‑929 fibroblasts) and ISO 10993‑11 systemic toxicity protocols before downstream melt‑spinning into monofilament sutures or injection moulding of resorbable bone‑fixation pins is permitted. Retention of the N‑benzyl and methyl ester protecting groups during polymerisation raises the glass transition temperature by 7°C compared to the fully deprotected analogue, a shift that widens the processing window for hot‑melt extrusion of drug‑eluting coatings.

How does the N‑benzyl carbamate formed in situ from this ester scaffold direct the regioselectivity of Curtius rearrangement to yield a cis‑4‑aminoproline building block?

When pharmaceutical programmes demand a cis‑oriented 4‑amino substituent on the pyrrolidine ring for constrained peptidomimetics, the methyl ester functionality is saponified with 1.1 equivalents of lithium hydroxide in a THF/water biphasic system at 0–5°C to liberate the free acid without ring‑opening. Conversion to the mixed anhydride using isobutyl chloroformate (1.0 eq) and N‑methylmorpholine at −20°C is followed by reaction with sodium azide (1.5 eq) to form the carbonyl azide; thermal rearrangement in toluene at 80°C generates the N‑benzyl‑cis‑4‑isocyanatopyrrolidine, which is immediately trapped with benzyl alcohol to produce the orthogonally protected cis‑diamino ester. Any unreacted azide is quenched with sodium nitrite and destroyed before aqueous work‑up, in compliance with explosive‑decomposition hazard assessments under EC Regulation 1272/2008 (CLP). This sequence is routinely executed at 5‑kg input scale in a 100‑L Hastelloy reactor with a rupture disc rated for a 100 bar·L explosion containment limit, and the isolated bis‑benzyl‑protected product attains a chemical purity of >99.5% (AUC, 210 nm) with the (2S,4R) diastereomer below 0.3%. The cis‑diamino scaffold is thereafter incorporated into 14‑membered macrocyclic peptidomimetics that target the PD‑L1 /B7‑H1 interface, formulated as lyophilised powders for intravenous infusion.